What records are connected here?
- Evidence lanes
- 3
- Source years
- 14
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Limited human dataNot a peptideMetabolic and weight
Also called Myalept1
Not a peptide: a protein, larger than a peptide, often looked up alongside peptides.
Metreleptin is a lab-made form of the fat-cell hormone leptin, with one extra amino acid, and the active ingredient in Myalept. At 147 amino acids it is a protein under FDA’s definition, not a peptide.1,3 FDA approved Myalept in 2014 to treat the complications of leptin deficiency in people with congenital or acquired generalized lipodystrophy, a lack of body fat tissue, alongside diet.1,2 Its label carries a boxed warning about antibodies that can neutralize leptin and about T-cell lymphoma, and it is available only through a restricted program.1
| Substance type | Not a peptide. The Myalept label states that metreleptin is 147 amino acids long, and FDA’s 2020 rule defines a protein as a chain of more than 40 amino acids.1,3 |
|---|---|
| What it is | Recombinant methionyl-human leptin: human leptin with an added methionine at its start, 147 amino acids long, made in E. coli, according to the label.1 |
| FDA status | FDA-approved. Drugs@FDA lists Myalept, application 125390, with an original approval date of February 24, 2014. The label has a boxed warning about neutralizing antibodies and lymphoma.1,2 |
| Human evidence | An open-label, single-arm study in 48 people with generalized lipodystrophy, described in the label.1 |
| Evidence strength | Limited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned |
Metreleptin is a recombinant analogue of human leptin made in E. coli. The label states that it differs from natural leptin by one added methionine and is a nonglycosylated chain of 147 amino acids.1
FDA’s 2020 rule defines a protein as a chain of more than 40 amino acids, so metreleptin counts as a protein, not a peptide.1,3
In the United States it is the active ingredient of Myalept, approved under application 125390, according to Drugs@FDA.2
Leptin is a hormone made mainly by fat tissue that tells the brain about the body’s energy stores. In generalized lipodystrophy, a lack of fat tissue leads to very low leptin, high triglycerides and fat build-up in the liver and muscle, according to the label.1
Metreleptin binds to and activates the leptin receptor, replacing the missing hormone, according to the label.1
The label describes an open-label, single-arm study in 48 people with generalized lipodystrophy and diabetes, high triglycerides or high fasting insulin; most were under 18.1
At one year, mean HbA1c fell by 2 percentage points, mean fasting glucose also fell, and median fasting triglycerides fell by 55%. The label notes that other diabetes and lipid medicines were not held constant during the study.1
Evidence-strength label: Limited human data. How this label is assigned
Yes. Drugs@FDA lists Myalept, application 125390, with an original approval date of February 24, 2014.2
The Myalept label cited here (DailyMed SPL version 18, published March 10, 2025) states that it is indicated, as an adjunct to diet, as replacement therapy for the complications of leptin deficiency in people with congenital or acquired generalized lipodystrophy, and that it is not established for partial lipodystrophy, liver disease or HIV-related lipodystrophy.1
The label carries a boxed warning that antibodies that neutralize leptin have developed in treated patients, with possible loss of effect and severe infections, and that T-cell lymphoma has been reported in people with acquired generalized lipodystrophy, whether or not they were treated. It is available only through a restricted program, the Myalept REMS.1
How much of the improvement is due to metreleptin itself, since the main study had no comparison group and other medicines changed during it.1
The long-term consequences of the neutralizing antibodies, which the label states are not well characterized.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Metreleptin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Metreleptin are a bounded selection, not every registration or paper about Metreleptin. For the years before Metreleptin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Metreleptin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Metreleptin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Myalept for generalized lipodystrophy. Approval rests on an open-label, single-arm study in 48 people. The label carries a boxed warning about neutralizing antibodies and lymphoma.↗↗
Status sources checked through November 16, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Myalept for generalized lipodystrophy. Approval rests on an open-label, single-arm study in 48 people. The label carries a boxed warning about neutralizing antibodies and lymphoma.↗↗
The cited status sources were checked through November 16, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date November 9, 2026
ClinicalTrials.gov record NCT02262806↗Added to PeptideScanner November 16, 2026Regulatory · added November 17, 2026
Federal Register notice 2016-22935↗Source date September 23, 2016Regulatory · added November 17, 2026
Drugs@FDA application BLA125390↗Source date February 24, 2014Regulatory · added November 17, 2026
Federal Register notice 2013-25588↗Source date October 30, 2013PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
24 of 25 selected trial records include at least one phase value; 25 of 25 include a status value in the retained structured contract.
A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”
15 of 15 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
The official Drugs@FDA dataset lists original submission 1 for BLA 125390 with status AP dated 2014-02-24, and names metreleptin among the application record's active ingredients.
The Federal Register published notice 2013-25588, attributed to FDA and its parent HHS department, on 2013-10-30. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin.
The Federal Register published notice 2016-22935, attributed to FDA and its parent HHS department, on 2016-09-23. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MYALEPT,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin.
15 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span October 30, 2013 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02262806 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05164341 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Literature metadata
PubMed lists PMID 34571177 in Presse medicale (Paris, France : 1983) as Journal Article, Review, with publication-date metadata of 2021-09-24 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02262832 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Literature metadata
PubMed lists PMID 42222073 in Frontiers in endocrinology as Case Reports, Journal Article, with publication-date metadata of 2026-05-13 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06305182 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02325674 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06679270 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Literature metadata
PubMed lists PMID 27717125 in Diabetes, obesity & metabolism as Case Reports, Letter, with publication-date metadata of 2016-11-09 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04026178 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-11-26, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Literature metadata
PubMed lists PMID 41080980 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-10-09 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 40860570 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-08-22 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
Federal Register · Official source · Source checked November 16, 2026